UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

## NOTICE OF ALLOWANCE AND FEE(S) DUE

7590

03/05/2007

CHRISTOPHER DEVRIES
General Motors Corporation
Mail Code 482-C23-B21, Legal Staff
P.O. Box 300
Detroit, MI 48265-4969

EXA	AMINER
CAMBY,	RICHARD M
ART UNIT	PAPER NUMBER
3661	

DATE MAILED: 03/05/2007

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/720,624	11/24/2003	Her ve Scelers	GP-303493	4260

TITLE OF INVENTION: SPEED SENSOR INSTABILITY DETECTION

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1400	\$300	\$0	\$1700	06/05/2007

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

## HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

- A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.
- B. If the status above is to be removed, check box 5b on Part B Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

- A. Pay TOTAL FEE(S) DUE shown above, or
- B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.
- II. PART B FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.
- III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

VEAS Appl. No. 10/642,763 October 23, 2006

- 24. (Currently Amended) Compositions according to claim 22, characterized in that the first means are vectors <u>comprising genes</u> expressing the target receptor(s)-at their surface.
- 25. (Previously Presented) Compositions according to claim 22, characterized in that the first means are liposomes bringing the said receptor(s) to their surface.
- 26. (Previously Presented) Compositions according to claim 22, characterized in that the second means are previously transformed cells with a vector carrying at least one bonding region to at least one receptor.
- 27. (Previously Presented) Compositions according to claim 22 characterized in that the second means are made from viral vectors carrying at least one bonding region to a target receptor.
- 28. (Previously Presented) Compositions according to claim 22, characterized in that the second means used are infected cells that produce pathogenic agents or are composed of infectious pathogenic agents.
- 29. (Previously Presented) Compositions according to claim 22, characterized in that the said pathogenic agents are viruses.
- 30. (Previously Presented) Compositions according to claim 29, characterized in that the pathogenic agent is HIV.

- 31. (Previously Presented) Compositions according to claim 22, characterized in that the said preparations are obtained by incubation of first means expressing the CD4 receptor and/or HIV co-receptors with second means expressing at least the preserved regions in gp120 or gp160 envelope proteins.
- 32. (Previously Presented) Compositions according to claim 31, characterized by the fact that the first means used are composed of autologous cells of mammals stimulated so as to express the CD4 receptor and/or HIV co-receptors, in a sufficient quantity for the required interaction.
- 33. (Currently Amended) Compositions according to claim 31, characterized in that the first means are viral vectors <u>comprising genes</u> expressing CD4 and/or HIV coreceptors-such as *baculovirus*, the Semliki forest virus or yeast such as *Saccharomyces* cerevisae, at their surface.
- 34. (Previously Presented) Compositions according to claim 31, characterized in that the first means are liposomes expressing the CD4 receptor and/or HIV co-receptors at their surface, the said expression being made by viral vectors.
- 35. (Currently Amended) Compositions according to claim 31, characterized in that the second means are composed of previously transformed cells with a viral vector comprising at least the preserved-regions [[in]]of HIV-1 gp120 or HIV-1 gp160 envelope proteins, or are composed of such viral vectors.

- 36. (Previously Presented) Compositions according to claim 31, characterized in that the second means are infected cells producing HIV or are composed of the HIV virus itself.
- 37. (Currently Amended) Compositions according to claim 31, characterized in that the second means are composed of <u>HIV-1 gp120</u> or <u>HIV-1 gp160</u> envelope proteins in natural or recombining form, or of at least the preserved regions of these proteins.
- 38. (Currently Amended) Compositions according to claim 31, characterized in that one of the co-receptors of HIV is replaced by a monoclonal antibody directed to a region of gp120 which binds to HIV-1 co-receptors.

Claim 39. (Cancelled)

- 40. (Previously Presented) Compositions according to claim 22 characterized in that the preparations are fixed with aldidrithiol-2 after incubation.
- 41. (Currently Amended) An isolated [[serums]]serum or antibody formed against a composition according to claim 22.
- 42. (Currently Amended) <u>Compositions Vaccinal compositions against an</u> infectious pathology intended for administration to a mammal, characterized in that they contain an effective quantity of an immunogenic composition according to claim 22, <u>further comprising [[with]]</u> an inert vehicle acceptable for administration to a mammal, and optionally with an additive.

- 43. (Previously Presented) Compositions according to claim 24, characterized in that the vectors are viral vectors.
- 44. (Currently Amended) Compositions according to claim [[29]]28, characterized in that the viruses pathogenic agents are selected from the group consisting of a retrovirus, a bacteria, a mycobacteria, and a parasite.
- 45. (Currently Amended) Compositions according to claim [[24]]28, characterized in that the viruses-pathogenic agents are selected from the group consisting of a Plasmodium sp, a Leishmania sp, Trypanosoma cruzi and Trypanosoma brucei.
- 46. (new) A composition according to claim 23, characterized in that the first means are healthy human cells taken from a patient to be vaccinated.
- 47. (new) Compositions according to claim 33, wherein the vectors are a baculovirus or the Semliki forest virus.
- 48. (new) Compositions according to claim 31, characterized in that the first means are yeast expressing CD4 and/or HIV co-receptors at their surface.
- 49. (new) Compositions according to claim 48 wherein said yeast are a Saccharomyces cerevi.